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Abstract: Italy has one of the highest paediatric cancer incidence rates in Europe. We compared cancer
incidence and survival rates in children (0–14 years) and adolescents (15–19 years) residing in Palermo
Province (PP) with statistics derived from Italian and European surveillance systems. We included all
incident cancer cases, malignant tumours and non-malignant neoplasm of central nervous system
(benign and uncertain whether malignant or benign), detected in children and adolescents by the
Palermo Province Cancer Registry (PPCR) between 2003 and 2012. A jointpoint regression model
was applied. Annual Average Percentage Changes were calculated. The Besag–York-Mollie model
was used to detect any cluster. The 5-year survival analysis was computed using Kaplan-Meier and
actuarial methods. We identified 555 paediatric cancer incident cases (90% “malignant tumours”).
No difference in incidence rates was highlighted between PPCR and Italy 26 registries and between
PPCR and Southern Europe. No jointpoint or significant trend was identified and no cluster was
detected. The 5-year overall survival didn’t differ between PP and the Italian AIRTUM pool.
A borderline higher statistically significant survival was observed in age-group 1–4 when comparing
PPCR to EUROCARE-5. The epidemiological surveillance documented in the PP was a paediatric
cancer burden in line with Italy and southern Europe. The study supports the supplementary
role of general population-based cancer registries to provide paediatric cancer surveillance of
local communities.
Keywords: cancer in childhood and adolescence; population-based cancer registries; epidemiological
surveillance; cancer incidence; cancer survival; jointpoint regression; time trends
1. Introduction
Even if childhood cancer is a rare event [1], it is one of the major causes of death in the younger
ages of life [2]. Childhood cancer has a worldwide impact of about 100,000 deaths every year before
the age of 15, more than 90% of which occur in resource-limited countries [3,4]. Despite important
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therapeutic progress and improvement in survival statistics [5–8], paediatric (0–19) cancer is still a
major global health issue with a strong ethical impact [9].
Recent data provided by the third volume of the International Incidence of Childhood Cancer
(IICC-3) highlighted a worldwide variation in the overall incidence of childhood cancers by
geographical region; the southern European region being the one with the highest rates at 0–14 (world
age-standardised rate: 170.9 per million) and 15–19 (world age-standardised rate: 243.7 per million)
age groups [10]. Also, a clear increase in the overall rates of childhood neoplasm in the period between
the 1980s and the 2000s has been documented [11,12].
In Italy, a significant increase in malignant cancer incidences was observed in children (0–14 years)
until 1997, with an Annual Percentage Change (APC) of +3.2%, followed by a plateau, while a
significant increase in incidence rate was observed in adolescents (15–19 years) between 1998 and
2008 [13]. Data collected by the Italian Network of Cancer Registries (AIRTUM), with regard to the
26 Italian local cancer registries over the period between 1992–2013, confirmed Italy as one of the
European countries with the highest incidence rates, ranking third place for both the 0–14 and 15–19 age
groups, with a standardized incidence rate of 186.1 per million persons-years and 275.4 per million
persons-years, respectively [12].
As reported by the population-based study Eurocare-5, providing survival estimates from
113 European cancer registries, between 2000 and 2007 the 5-year overall survival for childhood cancers
in Europe has raised to 77.9% (95%CI: 77.4–78.3%). However, despite the documented improvements
in survival, disparities between European countries are still observed, with the lowest outcomes
detected in Eastern Europe [14].
In Italy, in the last 15 years, malignant neoplasms occurring in the age-group 0–14 years have
shown a consistent 5-year survival improvement with a value of 82% documented in the period
between 2003–2008, while a 5-year survival of 86% was reported in adolescents aged 15–19 [13].
Furthermore, in Italy, no significant geographical heterogeneity in childhood cancer incidence
and survival rates was documented for any type of neoplasms nor for site groups, which is in contrast
to cancers that occurred in adults [13,15,16].
When compared to the adult population, paediatric patients are affected by different patterns of
cancer with peculiar biological and clinical aspects, including both typical childhood tumours and
other adolescent epithelial cancers mostly occurring in adults [11,17]. Leukaemia, central nervous
system (CNS) neoplasm and lymphoma are the most frequently diagnosed tumour types occurring in
children aged 0–14, while lymphomas and epithelial cancers are the most represented in the 15–19 age
group [1,7].
Despite the fact that aetiology of childhood cancer remains unclear, a possibly infectious
aetiology has been postulated [18], while genetic predisposition and environmental factors have
been investigated [19], being preconception, in-utero or postnatal environmental exposures, which are
all potentially implicated [20]. Therefore, childhood cancers have been investigated by cross-space-time
clustering analyses [21,22], emphasizing the importance of the surveillance activity performed
by population-based cancer registries, also in response to a specific increase in the demand for
epidemiological information coming from clinicians and local communities. In Italy, to date only three
specialised child and adolescent cancer registries are operative [23], while general population-based
cancer registries, covering any age-group including 0–19, are in charge of cancer surveillance for about
70% of the resident population [24].
Since 2003, the Palermo Province Cancer Registry (PPCR) provides the epidemiological cancer
surveillance of the fifth most populated area of Italy, with about 1,250,000 residential inhabitants,
including a 0–19 year old sub-population of 268,727 subjects (139,811 residing in the Palermo
metropolitan area only and the remaining residents in the surrounding 81 municipalities) [25].
In order to investigate the role of the general, population-based cancer registries (GPCRs) with
regard to paediatric cancer surveillance, we analysed data of cancer incidences and survival during a
ten-year period in child (0–14 years) and adolescent (15–19 years) residents in the Palermo Province (PP).
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A further comparison of cancer’s epidemiological impact on childhood and adolescence between PP
and data derived from the Italian and European surveillance systems was performed.
2. Materials and Methods
According to standards and guidelines for cancer registration in Europe provided by European
Network cancer registries [26] and the International Agency for Research on Cancer (IARC) [27],
we have selected all incidents of tumour cases (“all tumours”), including malignant tumours, as defined
according to the fifth digit of the morphology code (behaviour/3), and non-malignant neoplasm of
the central nervous system (benign and uncertain whether malignant or benign), coded by using the
ICD-O classification III edition (ICD-O-3) [28], which occurred between 2003 and 2012 in resident
children (0–14 years-old) and adolescents (15–19 years-old) in the PP. Then, all tumour cases were
manually trans-coded by using the third revision of International Classification of Childhood Cancer
(ICCC-3) [29].
Furthermore, according to the recommendations for a standard dataset for the European
Network of Cancer Registries [26], we have explored the following quality indicators of registration:
(a) percentage of microscopic verification (MV%): diagnosis based on cytology and/or histology of a
metastasis and/or histology of a primary tumour; (b) percentage of Death Certificate Only (DCO%):
diagnosis made from death certificate (no information available except the cause and the date of
death); c) percentage of non-microscopic verification (NMV%): diagnosis made before death and based
only on clinical-instrumental investigation, except histology. There was no case with an “unknown”
basis of diagnosis. Cases microscopically verified ranged between 81.8% and 92.3% for “all tumours”
(Table 1a) and between 86.7% and 94.5% for “malignant tumours” (Table 1b), respectively, while only
one malignant case was reported as DCO.
Table 1. Paediatric incident tumours cases by type, age-group and gender. Palermo Province, 2003–2012.
(a) All Tumours
Cases in Study Quality Indicators *
Age Group M n (%) F n (%) Total n (%) M/F MV n (%) DCO n (%) NMV n (%)
0–14 201(64.4)
159
(65.4)
360
(64.9) 1.26
313
(86.9)
1
(0.3)
46
(12.8)
0 20(6.4)
13
(5.4)
33
(5.9) 1.54
28
(84.8)
0
(0.0)
5
(15.2)
1–4 64(20.5)
55
(22.6)
119
(21.5) 1.16
106
(89.1)
0
(0.0)
13
(10.9)
5–9 57(18.3)
38
(15.6)
95
(17.1) 1.5
82
(86.3)
0
(0.0)
13
(13.7)
10–14 60(19.2)
53
(21.8)
113
(20.4) 1.13
97
(85.8)
1
(0.9)
15
(13.3)
15–19 111(35.6)
84
(34.6)
195
(35.1) 1.32
177
(90.8)
0
(0.0)
18
(9.2)
0–19 312(100)
243
(100)
555
(100) 1.28
493
(88.8)
1
(0.2)
61
(11.0)
(b) Malignant Tumours
Cases in Study Quality Indicators *
Age Group M n (%) F n (%) Total n (%) M/F MV n (%) DCO n (%) NMV n (%)
0–14 175(62.7)
144
(65.2)
319
(63.8) 1.21
285
(89.4)
1
(0.3)
33
(10.3)
0 17(6.1)
13
(5.9)
30
(6.0) 1.31
26
(86.7)
0
(0.0)
4
(13.3)
1–4 57(20.4)
50
(22.7)
107
(21.4) 1.14
98
(91.6)
0
(0.0)
9
(8.4)
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Table 1. Cont.
(b) Malignant Tumours
Cases in Study Quality Indicators *
Age Group M n (%) F n (%) Total n (%) M/F MV n (%) DCO n (%) NMV n (%)
5–9 49(17.6)
33
(14.9)
82
(16.4) 1.48
72
(87.8)
0
(0.0)
10
(12.2)
10–14 52(18.6)
48
(21.7)
100
(20.0) 1.08
89
(89.0)
1
(1.0)
10
(10.0)
15–19 104(37.3)
77
(34.8)
181
(36.2) 1.35
171
(94.5)
0
(0.0)
10
(5.5)
0–19 279(100)
221
(100)
500
(100) 1.26
456
(91.2)
1
(0.2)
43
(8.6)
M: males; F: females; M/F: ratio between males and females; MV: microscopic verification; DCO: death certificate
only; NMV: non-microscopic verification. * There was no case with an “unknown” basis of diagnosis.
We have identified n. 555 neoplasms, n. 500 of which were “malignant tumours” (Table 1).
The tumour cases were further categorized in the 12 tumours’ main groups (Table 2).
Table 2. Childhood and adolescence tumours incident cases (n 555) by third revision of International
Classification of Childhood Cancer (ICCC-3) groups and age-group. Palermo Province, 2003–2012.
ICCC-3 Main Groups
Children (0–14 Age Group) Adolescents (15–19 Age Group)
n of Cases % n of Cases %
I LEUKEMIA 99 28 27 14
a Lymphoid 73 74 17 63
b Acute myeloid 20 20 9 33
c CMD - - - -
d MDS & other 3 3 1 4
e Unspecified 3 3 - -
II LYMPHOMA & RELATED 41 11 60 31
a Hodgkin 21 51 37 62
b Non-Hodgkin except BL 7 17 19 32
c Burkitt (BL) 6 15 1 1.5
d Lymphoreticular 6 15 2 3
e Unspecified 1 2 1 1.5
III CNS NEOPLASMS 91 25 24 12
a Ependymoma 3 3 1 4
b Astrocytoma 31 34 6 25
c CNS embryonal 8 9 5 21
d Other gliomas 7 8 2 8
e Other specified 11 12 5 21
f Unspecified CNS 31 34 5 21
IV NEUROBLASTOMA 37 10 - -
a (Ganglio) neuriblastoma 35 95 - -
b Peripheral nervous 2 5 - -
V RETINOBLASTOMA 6 2 0 0
VI RENAL TUMOURS 19 5 2 1
a Nephroblastoma 17 89 1 50
b Renal carcinoma 2 11 1 50
c Unspecified - - - -
VII HEPATIC TUMOURS 3 1 1 1
a Hepatoblastoma 3 100 - -
b Hepatic carcinoma - - 100 100
c Unspecified - - - -
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ICCC-3 Main Groups
Children (0–14 Age Group) Adolescents (15–19 Age Group)
n of Cases % n of Cases %
VIII BONE TUMOURS 18 5 12 6
a Oteosarcoma 8 44 1 8
b Chondrosarcoma - - - -
c Ewing & related 7 39 5 42
d Other specified - - - -
e Unspecified 3 17 6 50
IX SOFT TISSUE SARCOMA 20 6 11 6
a Rhabdomyosarcoma 10 50 1 9
b Fibrosarcoma 5 25 4 36
c Kaposi sarcoma - - - -
d Other specified 4 20 6 55
e Unspecified 1 5 - -
X GERM CELL TUMOURS 10 3 15 8
a CNS germ cell 2 20 10 66
b Other extragonadal 4 40 - -
c Gonadal germ cell 4 40 3 20
d Gonadal carcinoma - - 1 7
e Unspecified gonadal - - 1 7
XI CARCINOMA & MELANOMA 9 3 42 22
a Adrenocortical - - 1 2
b Thyroid 6 67 27 64
c Nasopharyngel 1 11 3 7
d Melanoma 1 11 3 7
e Skin carcinoma - - 4 10
f Other & unspecified 1 11 4 10
XII OTHER & UNSPEFIED 7 2 1 1
a Other specified - - - -
b Other unspecified 7 100 1 100
TOTAL 360 100 195 100
Absolute and relative frequencies, and male to female ratio when appropriate, were calculated.
The cancer incidence rate per million persons-years was standardized on European population (Std-EU)
and was computed for the 0–14 age group using the following weights per each age group: 0–4 = 0.8,
5–9 = 0.7, 10–14 = 0.7. Age-specific incidence rates per million persons-years were calculated for the
15-19 age group per year each year within the study period [13]. The rates were calculated using
the annual inter-census estimates between 2002–2012 of the resident population, males and females
aged 0–19 and by a single year of age, provided by the Italian Statistics Institute (ISTAT) [25]. Further,
a comparison between age-specific incidence rates (0, 1–4, 5–9, 10–14, 15–19) in the PP and in the pool
of the 26 Italian registries providing childhood cancer data for the period between 1992–2013 (26 Italian
registries) [10] was performed using Fisher’s test with a statistical significance set at p-value = 0.05.
Moreover, the comparison of cancer incidence in children and adolescents between PPCR and the
“southern European region” was performed using world standardized population rates (WSR) [11].
The time trends of cancer incidence rates were fitted under a log-linear model by using the
Jointpoint Regression Program software [30]. The jointpoint regression model was applied to identify
any modification in time trends for Std-EU rates in the 0–14 age-groups and age-specific incidence
rates for the 15–19 age-group. The permutation test obtained by the grid search method suggested
by Lerman [31] was used in order to determine the number of significant jointpoints between
2003–2012. Given the size of the available time series, the maximum detectable jointpoints was
equal to 1. Significance was set at α = 0.05 and the test was adjusted by using the Bonferroni correction.
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Any differences in Annual Percentage Changes (APCs) between the two time periods in consideration
were calculated.
Annual Average Percentage Changes (AAPCs) were calculated by fitting the squares’ regression
line to the natural logarithm of the rates. When the regression coefficient β is equal to zero then AAPC
equals zero.
The incident cancer cases were localized using a space-time combination of address and date
of diagnosis [32]. Standardized incidence ratio (SIR) for the ten-year study period was calculated by
indirect method for each PP municipality. To perform the spatial analysis, SIRs were corrected using
Besag-York-Mollie (BYM) Bayesian method [33]. SIR-BYM and the post-probability (PProb) maps were
generated. PProb higher than 0.95 was considered statistically significant.
The 5-year survival analysis was restricted to “malignant tumours” only. For multiple tumours
we followed the IARC-IACR rules [27]. End of follow-up was set at 31 December 2017. Cases lost to
follow-up were 0.8%.
The 5-year observed survival and 95% Confidence Intervals (CIs) in the age groups 0–14 and
15–19 were computed applying the Kaplan-Meier method to compare the results with AIRTUM pool,
available only for the time period between 2003–2008 [14], while the 5-year observed survival and
95%CIs in the age groups <1, 1–4, 5–9 and 10–14 were calculated by using the actuarial method to
make comparisons with the Eurocare-5 study, available only for the period between 2000–2007 [14].
The computed 95%CIs were used to visually compare the survival data observed in the PP with the
selected published data [13,14].
BYM estimation, cluster analysis and survival analysis were performed by using RStudio (version
0.98.945, RStudio Inc., Boston, MA, USA) for the software R (3.1.—2014-04-10, R Foundation for
Statistical Computing, Vienna, Austria) with packages INLA, DCluster and surv, respectively.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Ethics Committee of Palermo “Palermo 1“ (N. 05/2017).
3. Results
We identified 555 incidents of cancer cases (312 males and 243 females), defined as “all tumours”
including malignant tumours and non-malignant neoplasm of the central nervous system (benign and
uncertain whether malignant or benign), coded by using the ICD-O-3 [21], and registered in children
and adolescents by the PPCR between 2003 and 2012 (Table 1a). Within the study cohort, 500 cases
(279 males and 221 females) were “malignant tumours” (Table 1b). Moreover, the distribution of
incident cases was comparable for genders and age-groups in both “all tumours” and “malignant
tumours” categories, the observed frequency being higher in males than in females and the male to
female ratio being higher than 1 in all age groups.
Table 2 reports the frequency distribution of the incidents of cancer cases according to the 12 main
ICCC-3 groups for both 0–14 and 15–19 age categories. Within the age class, 0–14 Leukaemia was the
most frequent (28%), followed by CNS neoplasm (25%), Lymphoma & related (11%), Neuroblastoma
(10%), Soft tissue sarcoma (6%), Renal and Bone tumours (5% respectively), Germ cell and Carcinoma
& Melanoma (3% respectively), Others & unspecified tumours and Retinoblastoma (2% respectively),
and Hepatic tumours (1%).
Within the age-class 15–19 Lymphoma and related were the most represented (31%), followed
by Carcinoma & Melanoma (22%), Leukaemia (14%), CNS neoplasm (12%), Germ cell tumours (8%),
and Bone tumours and Soft tissue sarcoma (6% respectively), Renal and Others & unspecified (1%
respectively).
Figure 1 depicts the comparison between PPCR and “Italy 26 registries” for “all tumours”
age-specific incidence rates: there was no statistical difference (p-value > 0.05) in all of the considered
age-groups (<1, 1–4, 5-9, 10–14 and 15–19).
There was no difference when comparing incidence rates between PPCR (Std-EU = 182.3; 95%CI:
163.3–201.2) and “Italy 26 registries” (Std-EU = 180.0; 95%CI: 174.0–186.0) for the 0–14 age-group.
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No difference in children was reported when we compared incidences between PPCR (WSR = 185.6;
95%CI: 166.3–204.9) and “Southern European Region” (WSR = 170.9). In the same direction, incidences
of cancer in adolescents has not shown any difference between PPCR (ASR = 249.8; 95%CI: 214.7–284.8),
“Italy 26 registries” (ASR = 275.4; 95%CI: 262.4–288.4) and “Southern European Region” (ASR = 243.7)
(data not shown).
Figure 2 represents the results of the jointpoint regression model and the values of the AAPCs for
both “all tumours” (a) and “malignant cancers only” (b) in the study period. No jointpoint has been
identified in incidence time-trends for childhood and adolescent cancer groups for “all tumours” nor
for “malignant cancers only”.
Further, no statistically significant trend was detected in any considered age-group, neither for
“all tumours” nor “malignant tumours”.
Figure 3 shows the SIRs by age-group and by municipality of (a) “all tumours”, the (b) BYM
estimates and their (c) Pprobs. Despite the significance of many municipality SIRs (results not shown),
as the maximum Pprob value was of 88%, no significant BYM estimate was highlighted. Therefore,
no cluster was identified.
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legend. PPCR: Palermo Province Cancer Registry; 95%CI: 95% Confidence Intervals.
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Figure 2. Average Annual Percentage Changes for (a) “all tumours” (males and females together)
and (b) “malignant tumours”, by age-groups. Palermo Province, 2003–2012. Figure 2 legend. AAPC:
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Table 3 shows the comparison of the 5-year survival rate restricted to “malignant tumours”
between PPCR and Italian AIRTU pool [13] and between PPCR and EUROCARE-5 study [12].
A 5-year overall survival rate of 82% (95%CI: 78–87) for the childhood group and of 86% (95%CI:
81–91) for the adolescent group was documented in the PP during the study period, but no statistically
significant difference was reported with regard to the Italian AIRTUM pool (Table 3a).
Table 3. Comparison of five-year observed survival (%) and its 95%CI for “malignant tumours”:
Palermo Province Cancer Registry versus Italian AIRTUM pool (a) and versus Eurocare-5 study (b).
(a) 0–14 Years 15–19 Years
Observed ival % (Kaplan-Meier Method) Overall (95%CI) verall (95%CI)
PCR (2003–2012) 82% (78–87) 86% (81–91)
AI M PO L (2003–2008) 82% (80–83) 86% (84–87)
(b) Age Groups
Observe rvival % (Actuarial Method) <1 (95%CI) 1–4 (95%CI) –9 (95%CI) –14 (95%CI)
PCR (2003–2007) 86% (75–99) 86% (80–93) 1% (73–90) 0 (73–88)
E R CARE-5 (2000–2007) 78% (76–79) 79% (78–80) 78% (77–79) 77 (76–78)
- i l f 85 (95%CI: 74–98) for the <1 age-group, of 86% (95%CI: 80–93) for the
1–4 age-group, of 84% (95%CI: 76–93) for the 5–9 age-group and of 8 (95%CI: 78–93) for the
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10–14 age-group was documented in the PP, with a borderline higher statistically significant survival
in the age-group 1–4 when comparing PPCR to EUROCARE-5 (Table 3b).
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Figure 3. Spatial analysis of (a) SIRs of “all tumours”; (b) BYM estimates and their (c) post-probabilities
by municipality and by children and adolescent cancers. Palermo Province (males and females together),
2003–2012. SIR: Standardized Incidence Ratio; SIR-BYM: estimates of SIRs from Besag-York-Mollie
Bayesian model; PProb: post-probabilities of BYM models.
4. Discussion
This study reports incidences and survival statistics of tumour cases which occurred in childhood
(0–14 years) and adolescence (15–19 years) over a ten-year period in the PP. Our results summarize
the epidemiological impact of childhood and adolescence tumours on the fifth Italian administrative
most populated area within a country documenting one of the highest incidences of cancer rates
in Europe [13], allowing us at the same time to make comparisons between both national and
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European frameworks, particularly the southern European region, by using data derived from a
general population-based cancer registry.
We preferred to analyse data considering the 0–14 and 15–19 age categories, instead of the
commonly used 0–14 and 0–19 age-groups, according to the different characteristics of the tumours
occurring within the two chosen age-groups (distribution of neoplasm with heterogeneous prognosis,
treatment protocols and diagnostic-therapeutic strategies and host biology) [14] and the well-known
difficulties of adolescents to be diagnosed and properly cured. This choice was also related to the
availability of data deriving from a GPCR: as its registration rules, unlike paediatric-specialized cancer
registries, are not exclusively designed to collect data on paediatric cancers [34,35], GPCRs codify
childhood and adolescence incident tumour cases by using the third revision of the ICD-O-3 [28]
needing to trans-codify into ICCC-3 [29].
Cancers in childhood and adolescence in the PP were more frequent in males than females both
for “all tumours” and “malignant tumours”, as expected according to literature [36,37].
Uniformity with national statistics has been highlighted with regard to the relative frequency of
tumour types and the burden of disease. In fact, according to the 12 main ICCC-3 groups, the results
provided by PPCR showed the same ranking reported by literature [10], the Leukaemia group being
the most represented in the 0–14 age category, followed by CNS neoplasm and Lymphoma & related
neoplasm groups, while Lymphoma & related neoplasm groups ranked first followed by Carcinoma &
Melanoma and Leukaemia groups in the 15–19 age category.
Further, as compared to “Italy 26 registries” [13], the incidence rates per million persons-years
in specific age classes <1, 1–4, 5–9, 10–14 and 15–19 reported by the PPCR resulted in a substantial
overlapping. Also, the graphical representation of the age-specific incidence rates showed the classical
“U” shape documented by literature [36,37].
In the same direction, there was no difference in standardised incidence rates for all the considered
age-groups when comparing statistics provided by PPCR to “Italy 26 registries” or to data available
for the southern European region, depicting a local and national epidemiological context in line with
a wider area documenting the highest incidence rates in children and adolescents as compared to
the entire European region where, in the 1990s, an age-standardized cancer incidence rate of 130 per
million persons-years was documented among children aged between 0 to 14 years old, whilst, over
the period between 1995–2002, the annual overall incidence rate in adolescents (15–19 years) was of
157 per million persons-years [10,12].
Nevertheless, the evidences provided by jointpoint regression model and spatial analysis, taken
together, make us confident to state that—despite the relatively short observational time window
available - the surveillance system documented the absence of environmental risk areas as well as the
occurrence of any specifically relevant event in the PP during the study period.
Within the study limitations, the documented evidences of an improvement over time in
registration quality and population coverage of cancer registries [11,38], particularly, immediately after
the start-up period, should be taken into account when interpreting our data.
Moreover, despite the fact that clustering for childhood tumours has been reported in
literature, particularly for leukaemia, intracranial and intraspinal embryonal tumours, and Hodgkin
lymphomas [18,39,40], the scanty number of specific types of incident cancers registered by the
PPCR in a relatively short period made us hesitant to explore clusters for leukaemia or other specific
tumour sites.
The aforementioned limitations together with the documented evidence of an increase in the
overall rates of childhood neoplasm in the last decay [11,12] are crucial points to consider, since GPCRs
are currently involved in the communication of risk related to environment and cancers and their
mission includes the translation and dissemination of evidence to enable informed decision-making
and to empower the general population or other stakeholders, while at the same time preserving a
rigorous methodological approach [41]. Therefore, according to the available body of evidence, greater
attention should be paid with regard to childhood and adolescence tumours in order to explore the
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implementation of a complementary methodological approach to the commonly used graphical and
visual formats (choropleth maps, tables, etc.) also in the risk communication of cancer paediatric
burden to stakeholders, particularly to communities and local authorities [41].
Lastly, the comparison of the 5-year overall survival rate, restricted to “malignant tumours” only,
between data provided by PPCR and the Italian AIRTUM pool [13] has documented overlapping
values of point estimates and their CIs for both children and adolescents. Moreover, the 5-year survival
point estimates are higher in the PP when comparing the PPCR data with Eurocare-5 study [14],
representing survival data on a European scale, even if only a borderline higher statistically significant
survival observed in favour of the PP for age-group 1–4.
The previous findings can be explained by the presence of a high quality network of specialized
centers for the treatment of paediatric cancers in Italy, ensuring specific healthcare pathways and
protocols; also, in relation to the patients’ migration across the country [13].
5. Conclusions
The epidemiological surveillance conducted by the PPCR in the PP has highlighted a burden of
childhood cancer in line with the Italian and the southern European frameworks.
As authors agree with the recent proposal to “move towards pan-European coverage” by
implementing the institution of childhood specialized cancer registries on a national level [35], potential
perspectives for the future are to intensify the collaboration between PPCR and the European Network
for Cancer Research in Children and Adolescents [42], as well as with clinicians, as already documented
by the previous joint experience conducted by the Italian Association of Paediatric Haematology and
Oncology and the AIRTUM network [13]. In this context, the progressive adoption of the new
guidelines and recommendations, on which staging systems should be adopted by population-based
cancer registries for the major childhood cancers, will make it easy to perform comparative studies
on incidences and other outcomes of interest, particularly survival [43]. Nevertheless, if it seems
appropriate to think globally, then it is necessary to act locally in order to answer the health demands
of each specific community. To this end, the experience of the PPCR supports a supplementary role
of general population-based cancer registries, as compared to paediatric specialized cancer registries,
to carry out childhood and adolescence cancer surveillance with the aim to assess and control the
impact of cancerous diseases on local communities [44].
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AAPC Annual Average Percentage Changes
AIRTUM Italian Network of Cancer Registries
APC Annual Percentage Change
ASR age-specific rates
BL Burkitt Lymphoma
BYM Besag-York-Mollie
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Cis Confidence Intervals
CMD Chronic myeloid disorders
CNS Central Nervous System
EU European Union
GAM Geographical Analysis Machine
GPCR general population-based cancer registries
IARC International Agency for research on cancer
ICCC International Classification of Childhood Cancer
ICD-O International Classification of Diseases for Oncology
IICC International Incidence of Childhood Cancer
ISTAT Italian Statistics Institute
MDS Myelodysplastic syndromes
PP Palermo Province
PPCR Palermo Province Cancer Registry
PProb post-probability
SIR standardized incidence ratio
Std-EU Standardized by age on the European population
WSR World standardized rate
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